Genentech

Mission Bio Announces Over 20 Presentations Demonstrating the Utility of Tapestri Across AML, Multiple Myeloma, and Lymphoma at the 2023 ASH Annual Meeting

Retrieved on: 
Thursday, December 7, 2023

The widespread adoption of Tapestri for hematological research and therapeutic development signifies the importance of single-cell multi-omic data and indicates a potential new gold standard in precision medicine.

Key Points: 
  • The widespread adoption of Tapestri for hematological research and therapeutic development signifies the importance of single-cell multi-omic data and indicates a potential new gold standard in precision medicine.
  • Detected MRD-positive patients, which were deemed negative by MFC and PCR,
    Differentiated between clonal hematopoiesis (CH) clones and leukemic clones.
  • Data from other blood cancer studies will be presented by leading researchers in over 24 presentations leveraging Mission Bio’s Tapestri Platform, showcasing its broad application in hematology.
  • For a complete list of ASH presentations using Tapestri, please visit our website .

Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer and Strengthens Commercial Organization with New Executive Appointments to Lead Planned U.S. Commercial Launch of Oral ALZ-801/Valiltramiprosate in 2025

Retrieved on: 
Tuesday, December 5, 2023

“Alzheon’s novel therapeutic approach has an opportunity to transform the standard of care and improve access to treatment for all Alzheimer’s patients.

Key Points: 
  • “Alzheon’s novel therapeutic approach has an opportunity to transform the standard of care and improve access to treatment for all Alzheimer’s patients.
  • He has more than 20 years of commercial launch, sales, market access, and leadership experience in the biopharmaceutical industry.
  • Previously, Mr. Greene held commercial and executive roles at Janssen, Otsuka, and Biogen, with over a dozen launches in CNS disorders and Alzheimer’s.
  • Having these strong leaders further enhances our ability to establish critical partnerships and patient advocacy programs to support a successful commercial launch in 2025.”

Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Retrieved on: 
Tuesday, December 5, 2023

Overall survival data were immature at this time, but a clear positive trend has been observed.

Key Points: 
  • Overall survival data were immature at this time, but a clear positive trend has been observed.
  • “These pivotal study results for this inavolisib combination represent a transformative medical advance for people with PIK3CA-mutated HR-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development.
  • With this unique dual mechanism of action, inavolisib may provide well-tolerated, durable disease control and potentially improved outcomes for people with HR-positive/HER2-negative, PIK3CA-mutated advanced breast cancer.
  • Inavolisib is currently being investigated in three Phase III clinical studies in people with PIK3CA-mutated metastatic breast cancer (INAVO120, INAVO121, INAVO122) in various combinations.

Avoro Ventures Adds Mark Chin as a Partner

Retrieved on: 
Friday, December 1, 2023

Avoro Ventures, a global venture capital firm investing in life sciences, announced today that Mark Chin has joined the firm as a Partner, focused on its venture capital investment efforts.

Key Points: 
  • Avoro Ventures, a global venture capital firm investing in life sciences, announced today that Mark Chin has joined the firm as a Partner, focused on its venture capital investment efforts.
  • Mark has 15 years of healthcare experience across venture capital, strategy consulting, business and corporate development.
  • Prior to joining Avoro Ventures, Mark was a Managing Director at Arix Bioscience focused on private and public biotech investments.
  • Mark will be joining Uya Chuluunbaatar, PhD, as an Investment Partner working with Behzad Aghazadeh, PhD, Managing Partner of Avoro Ventures, and Garheng Kong, MD/PhD, Avoro Ventures Advisory Partner.

Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer

Retrieved on: 
Wednesday, November 29, 2023

Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer.

Key Points: 
  • Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer.
  • As part of the next growth phase of the company, Paolo Michieli, PhD, (Founder and formerly Chief Scientific Officer) and Torsten Dreier, PhD, (previously Chief Development Officer) will continue at Agomab as senior advisors and members of the Scientific Advisory Board (SAB).
  • “Angelika’s extensive experience and deep knowledge as a senior drug developer will be of great value to the Board and our company.
  • Andrea Sáez was COO/CSO at Origo Biopharma where she led the development of ALK5 inhibitor programs through preclinical and early clinical stages.

Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development

Retrieved on: 
Tuesday, November 21, 2023

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities and AI to speed up drug discovery and development.

Key Points: 
  • Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities and AI to speed up drug discovery and development.
  • The collaboration is designed to significantly enhance Genentech’s advanced AI research programs by transforming its generative AI models and algorithms into a next-generation AI platform, expediting the discovery and delivery of novel therapies and medicines to people.
  • The companies will join forces to accelerate and optimize Genentech’s proprietary machine learning (ML) algorithms and models on NVIDIA DGX Cloud , which provides a training-as-a-service platform built on dedicated NVIDIA AI supercomputing and software, including NVIDIA BioNemo for generative AI applications in drug discovery.
  • “Our collaboration to create Genentech’s next-generation AI platform will dramatically accelerate the pace of drug discovery and development.”
    The collaboration with NVIDIA complements Genentech’s AI/ML teams, which are developing and leveraging AI and ML foundational models across numerous research areas including diverse therapeutic modalities.

1910 Genetics Appoints Bridget Cole to Chief Scientific Officer

Retrieved on: 
Thursday, November 16, 2023

1910 Genetics , the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Bridget Cole to Chief Scientific Officer.

Key Points: 
  • 1910 Genetics , the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Bridget Cole to Chief Scientific Officer.
  • View the full release here: https://www.businesswire.com/news/home/20231116571874/en/
    Bridget Cole, Chief Scientific Officer at 1910 Genetics (Photo: Business Wire)
    Cole has over 25 years of drug discovery and clinical development experience, helping advance compounds from lead identification through late-stage clinical trials across a wide range of therapeutic areas.
  • I have never met anyone like Jen Nwankwo, and I love working with her and my 1910 colleagues to develop innovative solutions to merge technology with empirical biology to drive drug discovery programs,” said Bridget Cole.
  • 1910 is currently one of the only biotech companies using Microsoft’s Azure Quantum Elements to bring quantum computing power to scientific discovery.

Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “The Lineage team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs, supporting our alliances and working to establish new collaborations,” stated Brian M. Culley, Lineage CEO.
  • Interested parties may access today’s conference call and webcast, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.
  • A live webcast of the conference call will be available online in the Investors section of Lineage’s website.

Inductive Bio Emerges from Stealth, Unveiling an ML Platform to Accelerate Compound Optimization in Drug Discovery

Retrieved on: 
Wednesday, December 13, 2023

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Inductive Bio, a technology company developing a machine learning (ML) platform designed to dramatically accelerate the compound optimization process, emerged from stealth today with $4.3M in funding.

Key Points: 
  • NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Inductive Bio, a technology company developing a machine learning (ML) platform designed to dramatically accelerate the compound optimization process, emerged from stealth today with $4.3M in funding.
  • Their seed round was co-led by Andreessen Horowitz (a16z) Bio + Health and Lux Capital, with participation from Character, Bessemer Venture Partners, Alleycorp, and others.
  • Inductive Bio was co-founded by Josh Haimson and Ben Birnbaum who had previously built out the ML organization at Flatiron Health, which was acquired by Roche in 2018.
  • Denali has integrated custom ADME models from Inductive into their small molecule drug design platform to support rapid, data-driven decision making.

HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors

Retrieved on: 
Monday, December 11, 2023

Dr. Chabi has led programs across multiple therapeutic areas including neurology, immunology, oncology, and ophthalmology as well as applications of artificial intelligence.

Key Points: 
  • Dr. Chabi has led programs across multiple therapeutic areas including neurology, immunology, oncology, and ophthalmology as well as applications of artificial intelligence.
  • She is also serving on the Scientific and Medical Research Funding Grants Working Group at the California Institute for Regenerative Medicine.
  • Dr. Chabi expressed enthusiasm about joining NurrOn and shared, "I am honored to be a part of NurrOn's Board of Directors.
  • Dr. Chabi joins an esteemed group of professionals on the NurrOn Board, and her appointment aligns with the company's strategic goals for the future.